BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17324459)

  • 41. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
    Pinilla-Ibarz J; Cathcart K; Korontsvit T; Soignet S; Bocchia M; Caggiano J; Lai L; Jimenez J; Kolitz J; Scheinberg DA
    Blood; 2000 Mar; 95(5):1781-7. PubMed ID: 10688838
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
    Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
    Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
    Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autologous peptides eluted from acute myeloid leukemia cells can be used to generate specific antileukemic CD4 helper and CD8 cytotoxic T lymphocyte responses in vitro.
    Delluc S; Tourneur L; Michallet AS; Boix C; Varet B; Fradelizi D; Guillet JG; Buzyn A
    Haematologica; 2005 Aug; 90(8):1050-62. PubMed ID: 16079104
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes.
    Wagner WM; Ouyang Q; Pawelec G
    Cancer Immunol Immunother; 2003 Feb; 52(2):89-96. PubMed ID: 12594572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia.
    Klammer M; Waterfall M; Samuel K; Turner ML; Roddie PH
    Br J Haematol; 2005 May; 129(3):340-9. PubMed ID: 15842657
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.
    Cathcart K; Pinilla-Ibarz J; Korontsvit T; Schwartz J; Zakhaleva V; Papadopoulos EB; Scheinberg DA
    Blood; 2004 Feb; 103(3):1037-42. PubMed ID: 14504104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
    Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
    Møller GM; Frost V; Melo JV; Chantry A
    FEBS Lett; 2007 Apr; 581(7):1329-34. PubMed ID: 17349636
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autologous MHC-dependent leukaemia-reactive T lymphocytes in a patient with chronic myeloid leukaemia.
    Coleman S; Fisher J; Hoy T; Burnett AK; Lim SH
    Leukemia; 1996 Mar; 10(3):483-7. PubMed ID: 8642866
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease.
    Maslak PG; Dao T; Gomez M; Chanel S; Packin J; Korontsvit T; Zakhaleva V; Pinilla-Ibarz J; Berman E; Scheinberg DA
    Leukemia; 2008 Aug; 22(8):1613-6. PubMed ID: 18256684
    [No Abstract]   [Full Text] [Related]  

  • 53. Simultaneous cytokine analysis by cytometric bead array for the detection of leukaemia-reactive T cells in patients with chronic myeloid leukaemia.
    Westermann J; Lessen A; Schlimper C; Baskaynak G; le Coutre P; Dörken B; Pezzutto A
    Br J Haematol; 2006 Jan; 132(1):32-5. PubMed ID: 16371017
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
    Delirezh N; Moazzeni SM; Shokri F; Shokrgozar MA; Atri M; Kokhaei P
    Cell Immunol; 2009; 257(1-2):23-31. PubMed ID: 19306994
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
    Forster K; Obermeier A; Mitina O; Simon N; Warmuth M; Krause G; Hallek M
    Ann Hematol; 2008 Mar; 87(3):183-93. PubMed ID: 17960378
    [TBL] [Abstract][Full Text] [Related]  

  • 56. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
    Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
    Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mesenchymal stem cells in patients with chronic myelogenous leukaemia or bi-phenotypic Ph+ acute leukaemia are not related to the leukaemic clone.
    Wöhrer S; Rabitsch W; Shehata M; Kondo R; Esterbauer H; Streubel B; Sillaber C; Raderer M; Jaeger U; Zielinski C; Valent P
    Anticancer Res; 2007; 27(6B):3837-41. PubMed ID: 18225540
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations.
    Stoklosa T; Poplawski T; Koptyra M; Nieborowska-Skorska M; Basak G; Slupianek A; Rayevskaya M; Seferynska I; Herrera L; Blasiak J; Skorski T
    Cancer Res; 2008 Apr; 68(8):2576-80. PubMed ID: 18413724
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2.
    Mochimaru H; Nagai N; Hasegawa G; Kudo-Saito C; Yaguchi T; Usui Y; Kurihara T; Koto T; Satofuka S; Shinoda H; Ozawa Y; Tsubota K; Kawakami Y; Ishida S
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4795-801. PubMed ID: 17898306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Peptides spanning the fusion region of Abl/Bcr are immunogenic and sensitize CD8(+) T lymphocytes to recognize native chronic myelogenous leukemia.
    Wagner WM; Ouyang Q; Pawelec G
    Leukemia; 2002 Nov; 16(11):2341-3. PubMed ID: 12399986
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.